Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma | Zendy

James Larkin | Zendy; Paolo A. Ascierto | Zendy; Brigitte Dréno | Zendy; Victoria Atkinson | Zendy; Gabriella Liszkay | Zendy; Michele Maio | Zendy; Mario Mandalà | Zendy; Lev Demidov | Zendy; Daniil Stroyakovskiy | Zendy; L. Thomas | Zendy; Luis de la CruzMerino | Zendy; Caroline Dutriaux | Zendy; Claus Garbe | Zendy; Mika A. Sovak | Zendy; Ilsung Chang | Zendy; Nicholas W. Choong | Zendy; Stephen P. Hack | Zendy; Grant A. McArthur | Zendy; Antoni Ribas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Author(s) -

James Larkin,

Paolo A. Ascierto,

Brigitte Dréno,

Victoria Atkinson,

Gabriella Liszkay,

Michele Maio,

Mario Mandalà,

Lev Demidov,

Daniil Stroyakovskiy,

L. Thomas,

Luis de la CruzMerino,

Caroline Dutriaux,

Claus Garbe,

Mika A. Sovak,

Ilsung Chang,

Nicholas W. Choong,

Stephen P. Hack,

Grant A. McArthur,

Antoni Ribas

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1408868

Subject(s) - vemurafenib , medicine , hazard ratio , oncology , placebo , interim analysis , melanoma , confidence interval , progression free survival , clinical endpoint , v600e , randomized controlled trial , gastroenterology , overall survival , metastatic melanoma , cancer research , cancer , pathology , mutation , biology , biochemistry , alternative medicine , gene

The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research